Additionally, it has been proposed that secukinumab could enhance the autophagic cell death of HCC by reducing IL-17-induced BCL2 expression, thereby inhibiting HCC carcinogenesis (173). The gene discussed is BCL2; the disease is hepatocellular carcinoma.